Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
- Silo Pharma, Inc. files a provisional patent application for SP-26 implantable drug delivery system
- The patent application focuses on time-released, dose-controlled formulation of ketamine for fibromyalgia
- CEO Eric Weisblum highlights the potential of SP-26 for sustained relief of chronic pain
- Pre-clinical studies show promising results for the SP-26 implant
- The next tests will measure drug dissolution and time-release action of the SP-26 ketamine implant
- None.
The recent announcement by Silo Pharma regarding their SP-26 implantable drug delivery system represents a significant advancement in the field of pain management, particularly for conditions like fibromyalgia. The stability of a time-release and dosage control system is a key factor in ensuring patient compliance and minimizing side effects, which are common issues with current pain management therapies.
From a pharmaceutical development perspective, the provisional patent application not only protects Silo's intellectual property but also potentially extends the commercial life of their product. If the SP-26 system proves to be effective in the next phases of testing, it could lead to a shift in how chronic pain is treated, moving away from systemic oral medications to localized, controlled delivery systems.
However, it's essential to remain cautious as the product is still in the pre-clinical stage. The transition from pre-clinical studies to human trials often uncovers new challenges and not all treatments that show promise in early testing become commercially viable. The true test will come during clinical trials when the safety and efficacy of SP-26 can be evaluated in a real-world setting.
The biopharmaceutical sector is highly competitive and innovations like Silo's SP-26 can have a notable impact on a company's market position. Investors typically respond positively to news of patent filings and successful pre-clinical studies, as they indicate progress in product development and a move towards potential FDA approval and market entry.
For Silo Pharma, a small-cap company, the progression of SP-26 through the development pipeline could significantly influence its stock valuation. Investors should monitor upcoming tests measuring drug dissolution and time-release action closely, as positive results could lead to increased investor confidence and potentially drive up the stock price.
It's important to note that while the news is promising, the investment community should balance their optimism with an understanding of the regulatory hurdles and the time required for drug development. Additionally, the market for chronic pain treatments is vast and the introduction of a novel drug delivery system could disrupt existing treatment paradigms and capture a substantial market share, if successful.
The strategic move by Silo Pharma to file a provisional patent application is a critical step in protecting their proprietary technology and securing a competitive edge in the marketplace. The patent process is intricate and securing a patent for a drug delivery system like SP-26 can provide Silo with exclusive rights to the technology, potentially blocking competitors from entering the space with similar products.
While the patent application is an indicator of innovation, stakeholders should understand that the approval of a patent does not guarantee the commercial success of the product. It is the subsequent approval by the FDA and adoption by the healthcare system that will ultimately determine the financial impact of SP-26 on the company's bottom line.
Investors should also be aware that the patent landscape can be subject to litigation and any future disputes could affect the company's market position and financial health. Close attention to the legal aspects surrounding the patent can provide foresight into potential challenges that may arise.
Silo reports positive stability of SP-26 for time-release and dosage control
SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent and Trademark Office (USPTO).
The patent application includes protection for the Company’s SP-26 implantable drug delivery system for a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia. Silo believes that implantable drug delivery may be well-suited for chronic pain management.
“Our SP-26 implant technology is designed to deliver a steady, low dose of ketamine for sustained relief of chronic pain,” said Eric Weisblum, CEO of Silo. “We are pleased with the implant’s performance in pre-clinical studies to date. If approved, SP-26 could be the first at-home approved ketamine based therapeutic.”
The next tests of the SP-26 ketamine implant will measure drug dissolution and time-release action.
About SP-26
Silo’s SP-26 is a ketamine-based injectable dissolvable implant for the treatment of chronic pain and fibromyalgia. The subcutaneous implant is being designed to safely regulate dosage and time release, of the pain-relieving treatment. If clinically successful, SP-26 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What patent application did Silo Pharma, Inc. file?
What is the focus of the patent application?
Who highlighted the potential of SP-26 for chronic pain relief?
What are the results of pre-clinical studies on the SP-26 implant?
What will the next tests measure regarding the SP-26 ketamine implant?
